<?xml version="1.0" encoding="UTF-8"?>
<p>However, recently the randomized evaluation of COVID-19 therapy (RECOVERY) trial (NCT04381936) found that dexamethasone (6 milligrams/day for 10 days) can save lives in intubated COVID-19 patients. Dexamethasone treatment reduced the 28-day mortality by one-third in intubated patients with invasive ventilation and by one-fifth in cases of patients receiving oxygen; however, it was not effective for less severe patients who did not required respiratory support [
 <xref rid="B229-ijms-21-05559" ref-type="bibr">229</xref>,
 <xref rid="B230-ijms-21-05559" ref-type="bibr">230</xref>]. Therefore, reflecting its benefit, the NIH COVID-19 treatment guidelines panel recommended administration of dexamethasone (6 mg/day for up to 10 days) for mechanically ventilated and oxygen supplemented COVID-19 patients. However, the possible adverse effects of secondary infections and hypoglycemia should be considered by the treating clinicians [
 <xref rid="B2-ijms-21-05559" ref-type="bibr">2</xref>].
</p>
